JP Patent

JP7626702B2 — 癌の治療において使用するためのｃｓｆ１ｒ阻害剤

Assigned to デシフェラ・ファーマシューティカルズ，エルエルシー · Expires 2025-02-04 · 1y expired

What this patent protects

Patent listed against Romvimza.

Drugs covered by this patent

Romvimza (VIMSELTINIB) · Deciphera Pharms

Patent Metadata

Patent number: JP7626702B2
Jurisdiction: JP
Classification: —
Expires: 2025-02-04
Drug substance claim: No
Drug product claim: No
Assignee: デシフェラ・ファーマシューティカルズ，エルエルシー
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.